Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365997 | 1.00 | RXFP1 (0.38) | RXFP1KDM4EALDH1A1HPGDHTR1A | |
| SCHEMBL6773488 | 0.81 | ADRA2A (0.50) | HTR1ASLC6A4 | |
| SCHEMBL4821524 | 0.77 | TSHR (0.35) | HTR1ALMNATP53TSHRMAPK1 | |
| SCHEMBL4362041 | 0.77 | RXFP1 (0.32) | RXFP1HTR1AMTNR1AMTNR1B | |
| SCHEMBL4368745 | 0.77 | LMNA (0.40) | KDM4EALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL5103551 | 0.77 | LMNA (0.40) | KDM4EALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL4375168 | 0.76 | HTR1A (0.55) | RXFP1KDM4EALDH1A1HPGDHTR1A | |
| SCHEMBL4998334 | 0.76 | HTR1A (0.55) | RXFP1KDM4EALDH1A1HPGDHTR1A | |
| SCHEMBL4363794 | 0.76 | HTR1A (0.55) | RXFP1KDM4EALDH1A1HPGDHTR1A | |
| SCHEMBL4821516 | 0.76 | CA2 (0.38) | KDM4EALDH1A1HTR1ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7479500-B2 | Antidepressant piperidine derivatives of heterocyclefused benzodioxans | WYETH (US) | 2009-01-20 | — | — | US | disclosed |
| US-7419986-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7381723-B2 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2008-06-03 | — | — | US | disclosed |
| US-7335666-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1537122-B9 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1537122-B1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-7135479-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040147523-A1 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-29 | — | — | US | disclosed |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-6617334-B2 | Inhibiting the reuptake of serotonin in a subject suffering from postraumatic stress, ADD, premenstrual dysphoria, obesity, eating disorder, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-6613913-B2 | Intermediate for antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta [a]naphthalene | WYETH | 2003-09-02 | — | — | US | disclosed |
| US-20030134871-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | WYETH | 2003-07-17 | — | — | US | disclosed |
| US-6525075-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020183336-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | OPRD1, HTR1A, HTR1D | RXFP1 1629/4885KDM4E 1785/4885ALDH1A1 83/4885 |
| US-20030134871-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | OPRD1, HTR1A, HTR1D | RXFP1 1629/4885KDM4E 1785/4885ALDH1A1 83/4885 |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | RXFP1 3642/4885KDM4E 2180/4885ALDH1A1 822/4885 |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | RXFP1 4308/4885KDM4E 1518/4885ALDH1A1 2148/4885 |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | HTR1A, HTR5A, HTR1D | RXFP1 1189/4885KDM4E 2808/4885ALDH1A1 307/4885 |
| US-20020183336-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | HTR1A, HTR5A, HTR1D | RXFP1 2038/4885KDM4E 1624/4885ALDH1A1 292/4885 |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, CYP19A1, HTR5A | RXFP1 3713/4885KDM4E 1984/4885ALDH1A1 640/4885 |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CYP19A1, CRH, CYP17A1 | RXFP1 3347/4885KDM4E 2371/4885ALDH1A1 409/4885 |
| US-20040147523-A1 | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | HTR5A, OPRD1, CRH | RXFP1 3423/4885KDM4E 2974/4885ALDH1A1 363/4885 |
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | HTR5A, OPRD1, CRH | RXFP1 3310/4885KDM4E 2557/4885ALDH1A1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.